Figure 2.
Figure 2. BRAFV600E produces more aggressive disease in the Eμ-TCL1 mouse model. B-cell–specific expression of BRAFV600E significantly shortens (A) leukemia onset and (B) overall survival (P < .001 comparing BRAFVE vs BRAFWT and BRAFCA for both onset and overall survival).

BRAFV600Eproduces more aggressive disease in the Eμ-TCL1 mouse model. B-cell–specific expression of BRAFV600E significantly shortens (A) leukemia onset and (B) overall survival (P < .001 comparing BRAFVE vs BRAFWT and BRAFCA for both onset and overall survival).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal